Ann: Epichem enters voluntary liquidation, page-27

This may appear to be a disappointment but it could also be a blessing in disguise.

It is a business reality that Australian goods and services are undercut by cheaper overseas labour and production capabilities. Unfortunately Australia has slowly become the "Can't Do" nation over the past generations. We are incapable of having a local car manufacturing industry, we are incapable of recycling our own plastic waste, we sell off our resources.

Epichem is merely the latest victim of globalism.

The company focus is now 100% concentrated on generating a valuable commercial outcome for Monepantel in three key areas - Canine Lymphoma, Human MND and Human Cancer. I believe that anti-viral properties may also be in the mix, but I think Covid is a no-go zone.

There will be a clear mission for the new CEO and the BoD - to "Make It Happen".

On balance, I'm still confident in the value of MPL and the possibilities of a successful commercial outcome are increasing with every clinical trial result.

All in my own opinion. Keep the Faith.